Skip to main content

Table 1 Baseline characteristics of patients who underwent follow-up coronary angiography

From: Five-year follow-up of angiographic disease progression after medicine, angioplasty, or surgery

Characteristics MT
(n= 110)
PCI
(n= 146)
CABG
(n= 136)
p
Demographic profile     
   Age, y 59 ± 9 60 ± 9 61 ± 10 0.147
   Female (%) 29 35 26 0.286
Medical history (%)     
   Current Smoker 32 27 31 0.018
   Hypertension 55 60 63 0.016
   Diabetes mellitus 35 29 42 0.090
   CCS class I or III angina 79 92 88 0.012
Laboratory values, mmol/L     
   Total cholesterol 224 ± 39 227 ± 49 210 ± 43 0.007
   LDL cholesterol 151 ± 34 151 ± 88 140 ±37 0.032
   HDL cholesterol 37 ± 9 38 ± 10 36 ± 10 0.600
   Triglycerides 200 ± 136 189 ± 94 181 ± 109 0.348
Medications     
   Beta-blockers 79 79 86 0.209
   Calcium-channel antagonists 62 42 66 0.001
   Long-acting nitrates 90 84 82 0.0195
   ACE inhibitors 35 33 28 0.467
   HMG-CoA reductase inhibitors 26 16 13 0.024
   Aspirin 97 98 96 0.719
   Oral Hypoglycemic agents 14 8 12 0.333
   Insulin 16 16 11 0.649
Positive treadmill test % 75 72 71 0.766
Entry angiographic features     
   Mean ejection fraction 66 ± 25 67 ± 17 66 ± 19 0.328
   Double-vessel disease, % 46 45 60 0.654
   Triple-vessel disease, % 54 55 50 0.648
   Proximal LAD, % 88 90 91 0.232
Vessel Territory ≥ 70%, %     
   Left anterior descending 89 93 95 0.062
   Left circumflex 71 70 78  
   Right coronary artery 71 68 85  
Risk factor control at 5 years     
   Aspirin use, % 95 94 95 0.926
   Lipid-lowering drug, % 78 81 66 0.009
   Current smoker, % 22 16 12 0.023
Total Events     
   New intervention 24.2 32.2 3.5 0.001
   Acute myocardial infarction 6 11 6 0.224
   Stroke 2 3 2 0.884
   Angina at 5 years 45.2 22.8 25.8 0.001
  1. MT = medical treatment; PCI = percutaneous coronary intervention; CABG=coronary artery bypass graft; LAD = left anterior descending artery; ACE = angiotensin-converting enzyme, HMG-CoA = 3-hydroxy-3methylglutaryl-coenzyme-a, LDL and HDL = high- and low-density lipoprotein, respectively.